{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}],"title":"Complete Remission (CR)"},{"measurements":[{"groupId":"OG000","value":"23"}],"title":"Complete Remission with Incomplete Marrow Recovery (CRi)"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Partial Remission (PR)"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Morphologically Leukemia Free State (MLFS)"},{"measurements":[{"groupId":"OG000","value":"19"}],"title":"Resistant Disease (RD)"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Disease Progression (PD)"},{"measurements":[{"groupId":"OG000","value":"8"}],"title":"Discontinued With No Response Data (DS)"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"}],"units":"Participants"}],"description":"Best response determined using the IWG-AML response criteria during the course of treatment.\n\n* CR: ANC ≥ 10\\^3 /µL, platelet counts ≥ 10\\^5 /µL, RBC transfusion independence, and bone marrow with \\< 5% blasts;\n* CRi: lack of morphologic evidence of leukemia (blasts \\< 5%), and platelet counts \\< 10\\^5 /µL or ANC \\< 10\\^3 /µL;\n* PR: all of the hematologic values for a CR but with a decrease of at least 50% in the percentage of blasts to 5% to 25% in the bone marrow aspirate;\n* MLFS: \\< 5% blasts in an aspirate and/or bone marrow core sample;\n* RD: failure to achieve CR, CRi, PR; only including subjects surviving at least 7 days following completion of initial treatment cycle with evidence of persistent leukemia by blood and/or bone marrow examination;\n* PD: one or more of the following: ≥ 50% decrement from maximum response levels in neutrophils or platelets; a reduction in hemoglobin by at least 2 g/dL; or transfusion dependence not due to other toxicities and bone marrow blast ≥ 5%.","groups":[{"description":"Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 50 mg, and increased up to 600 mg by Day 6. Beginning with Cycle 2, 600 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received LDAC (20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle.\n\nParticipants could continue receiving treatment until disease progression or until discontinuation criteria were met.","id":"OG000","title":"Phase 1+2: 600 mg Venetoclax + LDAC"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All enrolled participants who received venetoclax with LDAC at the recommended Phase 2 dose (600 mg)","reportingStatus":"POSTED","timeFrame":"Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.","title":"Best Response Based on IWG Criteria","type":"SECONDARY","unitOfMeasure":"Participants"}